The POETIC-A trial (NCT04584853) is based on a different approach and selects patients whose tumor Ki67 level does not drop after 2 weeks of anti-aromatase neoadjuvant treatment and explores the benefit of adding abemaciclib as post-neoadjuvant treatment. This evidence concerns the gene MKI67 and neoplasm.